Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Inhibrx Biosciences and Connect Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 111.55%. Connect Biopharma has a consensus target price of $6.14, indicating a potential upside of 550.24%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Inhibrx Biosciences.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibrx Biosciences | $1.30 million | 1,057.12 | -$140.05 million | ($8.88) | -10.51 |
| Connect Biopharma | $60,000.00 | 991.46 | -$55.48 million | ($1.19) | -0.79 |
Connect Biopharma has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Inhibrx Biosciences and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx Biosciences | N/A | -563.90% | -83.48% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Institutional and Insider Ownership
82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Inhibrx Biosciences has a beta of 3.81, indicating that its stock price is 281% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.
Summary
Connect Biopharma beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.
About Inhibrx Biosciences
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
